Nivalis Therapeutics, Inc. (NVLS) Files An 8-K Other Events
Item 8.01Other Events
On November14, 2016, Nivalis Therapeutics,Inc. issued a press
release announcing completion of enrollment in the second of two
Phase 2 clinical studies of cavosonstat(N91115), a novel
stabilizer of the cystic fibrosis transmembrane conductance
regulator protein.A copy of the press release is attached as
Exhibit99.1 and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
Number and Description
|
99.1 |
Press Release, dated November14, 2016. |
2
About Nivalis Therapeutics, Inc. (NVLS)
